+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05234307

Phase 1b Study of PBF-1129 and Nivolumab for Treating Advanced Recurrent or Metastatic Non-Small Cell Lung Cancer

Led by Dwight Owen · Updated on 2026-02-06

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and best dose of a combination treatment using PBF-1129, an adenosine A2B receptor antagonist, with nivolumab in patients who have advanced non-small cell lung cancer NSCLC that has returned or spread to other parts of the body. This phase I trial aims to study side effects while also assessing how well the treatment controls the disease and affects survival. Additional goals include exploring biomarkers and immune cells related to the cancer and treatment response. In this dose-escalation study, participants take PBF-1129 orally once daily and receive nivolumab intravenously on the first day of each 28-day treatment cycle. Treatment continues until the disease progresses or unacceptable side effects occur. After finishing treatment, patients are followed every 12 weeks for up to one year to monitor long-term effects and outcomes. During the study, patients undergo evaluations to measure adverse events within 30 days after their last dose, as well as tumor response, disease control, survival rates, and progression-free survival for up to one year after stopping treatment. Researchers also collect tumor tissue and blood samples to study immune effects and predictive biomarkers. Participants must meet health criteria, comply with study procedures, and undergo regular monitoring to support safety and data collection throughout the trial.

CONDITIONS

Brief Title

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Research Team

T

The Ohio State University Comprehensive Cancer Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here